Gilead's Trodelvy Ignites Hope & Stock Frenzy with 38% Breast Cancer Breakthrough!

Merck's Breakthrough: Islatravir-Doravirine Matches Leading HIV Treatment in Pivotal Trials

A New Dawn in Lung Cancer Treatment: Gilead and Arcus's Investigational Therapy Shows Promising Survival Advantage

Gilead Secures Extended Runway for Blockbuster HIV Drug After Landmark Patent Settlements

The Great Pharma Debate: Which Giant Will Dominate Your Portfolio?

Game-Changing Partnership: Hanmi Pharmaceutical's Oral Delivery Platform Licensed to Gilead Sciences

Soaring Horizons: Cystic Fibrosis Therapeutics Market Set to Skyrocket to $39.15 Billion by 2034

Lupin's Latest Triumph: US FDA Greenlight for HIV Drug Ignites Stock Rally

A New Dawn: Revolutionary Long-Acting HIV Prevention Jab Set for Global Reach by 2027

Gilead Taps Veeva Vault CRM for Global Commercial Transformation

Xilio Therapeutics Soars 8% on Groundbreaking Cancer Drug Data and Strategic Gilead Investment

Gilead Sciences Pioneers Future of Manufacturing with New California Development Site

Healthcare's Pulse Check: Why High-Yield Dividends Might Be Your Best Bet in a Struggling Sector

A New Dawn in Oncology: Kite Pharma's $350 Million Acquisition of Interius Biotherapeutics Set to Revolutionize CAR T-Cell Therapy